Neoadjuvant and adjuvant treatment of renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 12, Issue 6, 2012, Pages 765-776

  Thillai, Kiruthikah ^a   Allan, Suzanne ^a   Powles, Thomas ^b   Rudman, Sarah ^a   Chowdhury, Simon ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

adjuvant; bevacizumab; cytoreductive nephrectomy; everolimus; neoadjuvant; pazopanib; renal cell carcinoma; sorafenib

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; FLUOROURACIL; GIRENTUXIMAB; INTERFERON; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; SUNITINIB; THALIDOMIDE; TUMOR VACCINE; UFT; VITESPEN;

ABDOMINAL ABSCESS; ANASTOMOSIS LEAKAGE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HERNIA; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PATIENT SAFETY; POSTOPERATIVE HEMORRHAGE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROMA; SURGICAL INFECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862871314     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.56     Document Type: Review

References (84)

1. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: ana lysis of the national cancer data bases. Cancer 113(1), 78-83 (2009).
2. Sun M, Thuret R, Abdollah F et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 59(1), 135-141 (2011).
3. Golimbu M, Tessler A, Joshi P, Al-Askari S, Sperber A, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology 27(4), 291-301 (1986).
4. Kim SP, Alt AL, Weight CJ et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J. Urol. 185(6), 2035-2039 (2011).
5. DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA. DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. DeVita VT, Lawrence TS, Rosenberg SA, Weinberg RA, Depinho RA (Eds). Lippincott Williams and Wilkins, PA, USA (2011).
6. Klatte T, Pantuck AJ. Molecular biology of renal cortical tumors. Urol. Clin. North Am. 35(4), 573-580 (2008).
7. Linehan wM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7(5), 277-285 (2010).
8. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 115(Suppl. 10), 2313-2320 (2009).
9. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
10. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584-3590 (2009).
11. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
12. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26(33), 5422-5428 (2008).
13. Escudier B, Eisen T, Stadler WM et al. Sorenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
14. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27(20), 3312-3318 (2009).
15. Sternberg CN, Davis ID, Jardiak J et al. Pazopanib in locally advanced or metastic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
16. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
17. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and ana lysis of prognostic factors. Cancer 116(18), 4256-4265 (2010).
18. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
19. Leibovich BC, Lohse CM, Crispen PL et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol. 183(4), 1309-1316 (2010).
20. Gudbjartson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur. Urol. 48(4), 593-600 (2005).
21. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 27(5), 612-624 (2003).
22. dePeralta-Venturina M, Amin M, Tamboli P et al. Sarcomotoid differentiation in renal cell carcinoma. Am. J. Surg. Pathol. 25(3), 275-284 (2001).
23. Flanigan RC, Polcari AJ, Hugen CM. Prognostic variables and nomograms for renal cell carcinoma. Int. J. Urol. 18(1), 20-31 (2011).
24. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166(1), 63-67 (2001).
25. Sorbellini M, Kattan MW, Snyder ME et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J. Urol. 173(1), 48-51 (2005).
26. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168(6), 2395-2400 (2001).
27. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19(6), 1649-1657 (2001).
28. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20(23), 4559-4566 (2002).
29. Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 97(7), 1663-1671 (2003).
30. Karakiewicz PI, Briganti A, Chun FKH et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol. 25(11), 1316-1322 (2007).
31. Rosenberg SA, Lotze MT, Muui LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 316(15), 889-897 (1987).
32. Fisher RI, Coltman CA, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 108(5), 518-523 (1988).
33. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 paitents with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
34. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003).
35. McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23(1), 133-141 (2005).
36. Klapper J, Downey SG, Smith FO et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 113(2), 293-301 (2008).
37. Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 19(2), 425-431 (2001).
38. Messing E, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. 21(7), 1214-1222 (2003).
39. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J. Clin. Oncol. 21(16), 3133-3140 (2003).
40. Passalacqua R, Buzio C, Buti S et al. Adjuvant low-dose interleukin-2 plus interon-alpha in operable renal cell cancer. A Phase III, randomized, multicenter independent trial of the Italian Oncology Group for Clinical Research(GOIRC). J. Clin. Oncol. 25(18S) (2007).
41. Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2 and interferon alpha2 based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br. J. Cancer 92, 843-846 (2005).
42. Aitchison M, Bray C, Van Poppel H et al. Final results from an EORTC(GU Group)/NCRI randomized Phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). J. Clin. Oncol. 29 (2011) (Abstract 4505).
43. Pizzocaro G, Piva L, Fronzo GD et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J. Urol. 138, 1379-1381 (1987).
44. Naito S, Kumazawa J, Omoto T et al. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Int. J. Urol. 4(1), 8-12 (1997).
45. Margulis V, Matin SF, Tannir N et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 73, 337-341 (2009).
46. Galligioni E, Quaia M, Nerlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin. Cancer 77(12), 2560-2566 (1996).
47. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363(9409), 594-599 (2004).
48. Scherr AJ, Lima JPS, Sasse EC, Lima CS, Sasse AD. Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-ana lysis. BMC Cancer 11, 115 (2011).
49. Fishman M, Antonia S. Specific antitumour vaccine for renal cancer. Lancet 363(9409), 583-584 (2004).
50. Wood C, Srivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPPC-96;vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised Phase III trial. Lancet 372(9633), 145-154 (2008).
51. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 3(1), 76-99 (2011).
52. Wood C, Srivastava P, Lacombe L et al. Survival update from a multicenter, randomized, Phase III trial of vitespin versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J. Clin. Oncol. 27(Suppl.), 15s (2009) (Abstract 3009).
53. Shuch B, Li Z, Belldegrun AS. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. Br. J. Urol. Int. 101(Suppl. 4), 25-30 (2008).
54. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl. J. Med. 345(23), 1655-1659 (2001).
55. Mickisch GHJ, Garin A, Poppel HV, Prijck LD, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001).
56. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Poppel HV, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined ana lysis. J. Urol. 171, 1071-1076 (2004).
57. Fallick ML, Mcdermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol. 158(5), 1691-1695 (1997).
58. Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185(1), 60-65 (2011).
59. Szczylik C, Porta C, Bracarda S et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5124).
60. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
61. Heng DYC, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large multicenter study. J. Clin. Oncol. 27(34), 5794-5799 (2009).
62. van der Veldt AA, Meijerink MR, van den Eertwegh AJ. Sunitinib for treatment of advanced renal cell cancer: primary tumour response. Clin. Cancer Res. 14(8), 2431-2436 (2008).
63. Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181(2), 518-523 (2009).
64. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P. Primary tumour response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol. 59(1), 10-15 (2011).
65. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survial in metastatic renal cell carcinoma patients treated with sunitinib. Eur. Urol. 60(6), 1273-1279 (2011).
66. Karakiewicz P, Suardi N, Jeldres C. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol. 53(4), 845-848 (2008).
67. Cost NG, Delacroix SE, Sleeper JP, Smith PJ. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval thrombus. Eur. Urol. 59, 912-918 (2011).
68. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 11(4), 373-382 (2010).
69. Margulis V, Matin SF, Tannir N, Tamboli P. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180(1), 94-98 (2008).
70. Thomas AA, Rini BI, Stephenson AJ, Garcia JA. Surgical resection of renal cell carcinoma after targeted therapy. J. Urol. 182(3), 881-886 (2009).
71. Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Postoperative complications from cytoredutive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 29(Suppl. 7) (2011) (Abstract 300).
72. Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(25), 4076-4081 (2009).
73. Cowey CL, Amin C, Pruthi RS, Wallen EM. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28(9), 1502-1507 (2010).
74. Hellenthal NJ, Underwood W, Penetrante R et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 184(3), 859-864 (2010).
75. Powles T, Blank C, Chowdhury S et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60(3), 448-454 (2011).
76. Bukowski R, Kabbinavar FF, Figlin RA et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell carcinoma. J. Clin. Oncol. 25(29), 4536-4541 (2007).
77. Oosterwijk E, Rathmell WK, Junker K et al. Basic research in kidney cancer. Eur. Urol. 60(4), 622-633 (2011).
78. ClinicalTrials.gov. Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer. http://clinicaltrials.gov/ct2/show/NCT00087022
79. ClinicalTrials.gov. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). http://clinicaltrials.gov/ct2/show/ NCT00930033
80. ClinicalTrials.gov. A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer (S-TRAC). http://clinicaltrials.gov/ct2/show/NCT00375674
81. ClinicalTrials.gov. Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery. http://clinicaltrials.gov/ct2/show/ NCT00326898
82. ClinicalTrials.gov. Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer. http://clinicaltrials.gov/ct2/ show/NCT00492258
83. ClinicalTrials.gov. A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT). http://clinicaltrials.gov/ct2/show/ NCT01235962
84. ClinicalTrials.gov. Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery. http://clinicaltrials.gov/ct2/show/NCT01120249